ATAXIA MARKET ANALYSIS

Ataxia Market, by Treatment Type (Pharmacotherapy (Levodopa, Pramipexole, Desvenlafaxine, Venlafaxine, and Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)), Physical Therapy, Speech Therapy, and Others (Adaptive Devices and Occupational Therapy)), by Disease Type (Friedreich's Ataxia, Ataxia-telangiectasia, Spinocerebellar Ataxias, Episodic Ataxia, and Others (Multiple System Atrophy (MSA))), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Oct 2021
Code : CMI4714
Pages :150
Formats :
Excel and PDF
Industry : Biotechnology

Ataxia MarketSize and Trends

The global ataxia market is estimated to be valued at US$ 30,880.5 million in 2021 and is expected to exhibit a CAGR of 9.4% over the forecast period (2021-2028).

The increasing incidence of ataxia is expected to drive the growth of the global ataxia market over the forecast period.

The increasing research and development activities for the development of novel therapeutics for the treatment of ataxia is expected to drive the market growth over the forecast period.

Figure 1. Global Ataxia Market Share (%), By Region, 2021